Sandoz to buy eye drug Cimerli in $170 million deal
ZURICH (Reuters) -Sandoz on Monday announced a deal to buy Cimerli, a biosimilar drug to treat vision impairment and loss, from Coherus BioSciences Inc. for …
sandoz
Sandoz dials up product launch plans ahead of market debut
By Ludwig Burger and Paul Arnold FRANKFURT (Reuters) – Sandoz plans to launch at least five additional biologic drugs, its CEO Richard Saynor said, as …
Sandoz launches rival version of AbbVie’s arthritis drug Humira
(Reuters) – Swiss drugmaker Sandoz said on Saturday it had launched a biosimilar version of AbbVie Inc’s big selling arthritis treatment Humira, adding to U.S. …
Novartis names Firmenich CEO as chairman designate of Sandoz
ZURICH (Reuters) – Novartis on Monday announced the appointment of Gilbert Ghostine as chairman-designate of Sandoz, the generics unit Novartis wants to spin off later …
Novartis plans to close a Sandoz plant in North Carolina
ZURICH (Reuters) – Pharmaceuticals company Novartis plans to close a Sandoz generics plant in Wilson, North Carolina, around the end of 2023, it said on …
Analysis-Novartis CEO may struggle to rally investors to Sandoz spin-off
By Natalie Grover LONDON (Reuters) – Novartis CEO Vas Narasimhan could struggle to woo investors to the listing of generics drugs business Sandoz, as weaker …